BYON3521 showed good potency and full efficacy in MET-amplified and high MET–expressing cancer cell lines; in moderate and low MET–expressing cancer cell lines good potencies and partial efficacy were observed. In mouse xenograft models, BYON3521 showed significant antitumor activity upon single-dose administration in multiple non-MET–amplified tumor types with low, moderate, and high MET expression, including complete tumor remissions in models with moderate MET expression....The performance of BYON3521 in vivo was evaluated in the gastric adenocarcinoma MKN-45 cell line–derived xenograft model (CDX; MET amplified), a mouse clinical trial (MCT) in patient-derived xenograft (PDX) models...